GNTA Stock Analysis: Buy, Sell, or Hold?
GNTA - Genenta Science S.p.A. American Depositary Shares
$1.01
0.01 (1.00%)
▲
5d:
-12.17%
30d:
-32.21%
90d:
-38.79%
WAIT
LOW Confidence
Analysis Updated: Aug 28, 2026 12:00 AM ET
Earnings: Mar 27, 2026
0d
Get Alerted When GNTA Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR STABILIZATION: GNTA is down 12.2% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
⏸️ WAIT FOR STABILIZATION: GNTA is down 12.2% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
In-depth Analysis How we analyze
Valuation Analysis: GNTA is currently trading at $1.01, which is considered oversold relative to its 30-day fair value range of $1.13 to $1.47.
Technical Outlook: Technically, GNTA is in a uptrend. The price is currently testing key support at $0.99. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock scores a mixed 43/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $6.98 (+598.0%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, GNTA is in a uptrend. The price is currently testing key support at $0.99. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock scores a mixed 43/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $6.98 (+598.0%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$1.13 -
$1.47
Company Quality Score
50/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
82.6%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (43/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 598.0% below Wall St target ($6.98)
- WARNING: Composite score 50/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$1.13 -
$1.47
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$0.99
Resistance Level
$1.33
Current Trend
Uptrend
Technical data as of
Aug 28, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-1.89
Wall Street Target
$6.98
(+598.0%)
Share & Embed Analysis
Last updated: August 31, 2026 11:21 AM ET
Data refreshes hourly during market hours. Next update: 12:21 PM
Data refreshes hourly during market hours. Next update: 12:21 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is GNTA showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ALNY
Alnylam Pharmaceuticals … |
STRONG BUY
30 analysts |
$370 | 41 HOLD |
|
ONC
BeiGene, Ltd. |
STRONG BUY
24 analysts |
$432 | 29 SELL |
|
VRTX
Vertex Pharmaceuticals I… |
BUY
34 analysts |
$563 | 31 SELL |
|
APLS
Apellis Pharmaceuticals … |
BUY
22 analysts |
$41 | 50 HOLD |
|
ASND
Ascendis Pharma AS |
STRONG BUY
16 analysts |
$313 | 43 HOLD |
